

INVASIVE CANDIDIASIS (CAGTA) VIRCLIA® IgG MONOTEST

Indirect chemiluminescent immunoassay (CLIA) to detect IgG antibodies against antigens located on the cell wall surface of the micelium of *Candida albicans* (CAGTA, Candida albicans germ tube antibody) in human serum/plasma.

- · Discriminates between infection and colonization.
- · High Negative Predictive Value (NPV).
- Objective method with extraordinary sensitivity and accuracy in the results.
- Highly convenient solution to urgent samples. Simple and automated protocol that provides results within 1 h.
- · Sample dispensed from primary tube.
- Individual Quality Control per monotest, no need for extra controls or calibrations.
- CAGTA (Candida albicans germ tube antibody) is widely recognized in the scientific literature as an excellent diagnostic tool.
- Compatible test with the broadest panel of infectious diseases in CLIA monotest format (>90 parametres).



VirClia® MONOTEST - 24 tests





INVASIVE CANDIDIASIS

Invasive candidiasis is an opportunistic disease of fungal etiology that can occur when *Candida* yeasts enter the bloodstream and spreads to other parts of the body causing an infection.

Antibodies to CAGTA are normally present in sera from patients with invasive candidiasis caused by *C. albicans* and other species of this genus.

Patients at high risk for developing candidemia include:

- Intensive care unit (ICU) patients.
- · Patients with major surgery.
- Patients with a central venous catheter.
- · People whose immune systems are weakened.
- Patients receiving broad spectrum antibiotic therapy.
- · Very low-birth-weight infants.





EARLY DETECTION OF INVASIVE CANDIDIASIS

Vircell has launched a new test for the early detection of invasive candidiasis (IC) that discriminates infection from colonization. A prompt and accurate diagnosis is essential as a delay of only 12 hours may affect survival significantly.

With this method, clinicians will be able to specifically treat the infective phase of Candida, avoiding for many patients to receive unnecessary, expensive and sometimes toxic antifungals.

INVASIVE CANDIDIASIS (CAGTA) VIRCLIA® IgG MONOTEST can bring significant advances to clinical laboratories where giving an informed result can truly make the difference in saving someone's life.

Clancy, C. J. and Nguyen, M. H. (2018) Diagnosing Invasive Candidiasis. Journal of Clinical Microbiology, 56 (5) e01909-17

Clancy, C. J. and Nguyen, M. H. (2018) Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. Journal of Fungi. 4, 27.

Lo Cascio, G. et al. (2018) Value of beta-D-glucan and CAGTA biomarkers in diagnosing invasive candidiasis among medical and surgical patients. ECCMID, Madrid, Spain.

Marchi, E. et al. (2018) Performance of the association of two markers for invasive candidiasis (IC): (1-3)-beta-D-glucan and C. albicans germ tube antibodies (CAGTA). ECCMID, Madrid, Spain

Why INVASIVE CANDIDIASIS (CAGTA) VIRCLIA® IgG MONOTEST should be part of your lab routine?

> Objective results in 1 hour

Early diagnosis and treatment are associated with a better prognosis in invasive candidiasis.

> On-demand testing

One monotest = one reportable result. Nothing else is required.

> Save costs

Using the right diagnostic tool could lead to substantial reductions in total inpatient cost.

> Better patient care

Giving unnecessary and expensive antifungal drugs to patients should be avoided.

INFORMATION AND RELATED PRODUCTS

Description	Cat. No.	Content / Capacity
INVASIVE CANDIDIASIS (CAGTA) VIRCLIA® IgG MONOTEST	VMC094	24 tests
ASPERGILLUS GALACTOMANNAN Ag VIRCLIA® MONOTEST	VCM073	24 tests
VIRCLIA® LOTUS	VCLTS-CL	40 monotests

